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Background: Several studies comparing the efﬁcacy and safety of prasugrel and clopidogrel in patients
undergoing percutaneous coronary angiography (PCI) have been reported. The preponderance of the
studies is in patients with acute coronary syndrome.
Methods and results: We studied the 30-day efﬁcacy and safety of prasugrel loading compared with
clopidogrel loading in 326 patients undergoing PCI for non-urgent indications (i.e. excluding patient with
myocardial infarction) who were anticoagulated with bivalirudin during the procedure. Patients loaded
with prasugrel were younger (63 vs 67; p = 0.007) and had more history of cerebrovascular disease
(15.6% vs 2.7%; p = 0.008), heart failure (12.8% vs 5.4%; p = 0.05) and prior PCI (32% vs 22%; p = 0.05).
Major adverse coronary events (MACE) and bleeding complications were analyzed during hospitalization
and at 30 days. The bleeding and ischemic complication rates were similar and low in both groups. During
hospitalization: MACE, 0.6% for clopidogrel vs 2.0% for prasugrel, p = 0.33; No Thrombolysis In Myocardial
Infarction (TIMI) major bleeding in either group; TIMI minor bleeding 1.1% vs 0%, p = 0.5; access site
hematoma 3.4% vs 2.0%, p = 0.3. At 30 days: MACE, 1.1% for clopidogrel vs 2.7% for prasugrel, p = 0.41;
TIMI major bleeding 0% vs 0.7%, p = 0.45; TIMI minor bleeding 2.2% vs 4.8%, p = 0.24. None of the differences
was statistically signiﬁcant.
Conclusion: At 30 days, there were no differences in MACE or bleeding complications in patients anticoagulated
with bivalirudin and given either clopidogrel or prasugrel during PCI for non-urgent indications.© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Introduction
In the TRial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet InhibitioN with Prasugrel Thrombolysis In
Myocardial Infarction (TRITON-TIMI 38) clinical trial, prasugrel use
in patients receiving it for angioplasty in the setting of ACS was
associated with fewer ischemic events than was clopidogrel. Prasugrelany grants or ﬁnancial support
00, Dallas, Tx 75226, United
8.
M. Schussler).
eliability and freedom from bias
nd Ltd. Open access under CC BY-NC-Nuse was, however, associated with an increased risk of major bleeding
[1]. Large-scale, randomized trials have also shown that the use of
bivalirudin instead of heparin plus a glycoprotein IIb/IIIa inhibitor
for anticoagulation during percutaneous coronary intervention (PCI)
results in fewer major and minor bleeding complications and less
thrombocytopenia [2–4] with no increase in the rate of adverse
ischemic outcomes after PCI. In these trials, platelet inhibition was
attainedwith a standard therapy of aspirin and clopidogrel or ticlopidine.
In TRITON-TIMI 38, bivalirudin was administrated in only 3% of trial
subjects undergoing PCI for acute coronary syndrome. Other smaller
studies evaluated the efﬁcacy and safety of prasugrel compared to
clopidogrel in patients undergoing PCI for acute coronary syndrome
and are anticoagulated with bivalirudin [5]. In our clinical practice,
bivalirudin is the anticoagulant of choice for both ACS as well as rou-
tine PCI, and the majority of procedures performed are for non-acute
diagnoses. The present study was undertaken to compare prasugrel
and clopidogrel antiplatelet therapy in patients undergoing PCID license.
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anticoagulated with bivalirudin.
Methods
We retrospectively reviewed the records for 326 consecutive
patients undergoing PCI at our institution using intraprocedural
bivalirudin anticoagulation between July 2009 and March 2013.
Patients were identiﬁed from an ongoing registry of coronary interven-
tions kept at our institution. We excluded patients undergoing PCI in an
urgent setting i.e. ST segment- or Non ST segment-elevationmyocardial
infarction. Patients who received peri-procedural ﬁbrinolytics were
excluded. Also, patients at increased risk of bleeding i.e. international
normalized ratio N 1.5, or a platelet count b 100000/mm3 at admission,
patients on oral anticoagulation or other antiplatelet therapy at the time
of the procedure were excluded. Any patient with a concomitant
medical illness that in the opinion of the investigators was associated
with reduced survival over the 30-day follow-up period was also
excluded. We compared patients receiving prasugrel to those receiving
clopidogrel as part of their dual anti-platelet therapy (DAPT) for PCI.
93% of patients had follow-up data available from a clinic visit within
the 30-days from the index PCI.
Prior to angioplasty, all patients received a bivalirudin bolus of
0.75 mg/kg, followed by an IV infusion at 1.75 mg/kg/h. All patients
were pretreated with aspirin 325 mg and received a 300- or 600-mg
dose of clopidogrel or 60 mg of prasugrel during the procedure (after
determination of the coronary anatomy and the decision to treat the
lesion with a stent) or just after the intervention. Operator discretion
dictated the choice of pharmacologic therapy. Glycoprotein IIb/IIIa
inhibitors were also administered at the physician's discretion andTable 1
Baseline characteristics.
Characteristic Clopidogrel (n = 179)
Age (years) 67.0 (SD: 11.6)
Men 106 (59.2%)
Body mass index (Kg/m2) 29.9 (SD: 7.0)
White 154 (86%)
Hispanic 7 (3.9%)
Black 14 (7.8%)
Systemic hypertension 151 (84.4%)
Family history of premature CAD 80 (44.7%)
Diabetes mellitus 62 (34.6%)
Dyslipidemia 163 (91.1%)
Current smoker 30 (16.8%)
Pervious myocardial infarction 35 (19.6%)
Previous PCI 57 (31.8%)
Previous coronary bypass 35 (19.6%)
Prior heart failure 23 (12.8%)
Ejection fraction 55 (SD: 12)
Prior valve surgery 2 (1.1%)
S. creatinine 1.1 (SD: 0.3)
End-stage renal disease 8 (4.5%)
Cerebrovascular disease 19 (15.6%)
Peripheral arterial disease 38 (21.2%)
Indication
Stable angina pectoris 53 (29.6%)
unstable angina pectoris 104 (58.1%)
Other 22 (12.3%)
Canadian Classiﬁcation Society (CCS) angina class
0 16 (8.9%)
l 2 (1.1%)
II 38 (21.2%)
III 116 (64.8%)
IV 16 (8.9%)
Medications
β blocker 110 (61.5%)
CCB 35 (19.6%)
Nitrates 11 (6.2%)
Ranolazine 4 (2.2%)
CAD: coronary artery disease; CCB: calcium channel blocker; PCI: percutaneous coronary angioaccording to guidelines (3 (1.7%) in the clopidogrel vs 2 (1.3%) in the
prasugrel group). The patientswere dischargedwith aspirin indeﬁnitely
and either clopidogrel 75 mg or prasugrel 10 mg for ≥3 months and
≥1 year, respectively, depending on the implanted stent. The analyzed
ischemic end points included all-causemortality, cardiac death, Q-wave
myocardial infarction (MI), non-Q-wave MI, unstable angina, target
vessel revascularization (TVR), and stent thrombosis. Major adverse
cardiac events (MACE) were deﬁned as death, MI, or symptom-driven
revascularization. Q-wave MI and non-Q-wave MI were deﬁned as the
rise of cardiac troponin above the 99th percentile for the upper limit
of normal, with associated EKG changes. Stent thrombosis was deter-
mined using the Academic Research Consortium deﬁnitions and includ-
ed both “deﬁnite” and “probable.” Bleeding complications included
Thrombolysis In Myocardial Infarction major and minor bleeding [6].
Statistical methods
Continuous variables are presented as mean with the standard
deviation (SD) and compared using Student's t test. Categorical
variables are expressed as absolute numbers and percentages and
were compared using the chi-square test or the Fisher exact test, as
appropriate. Statistical signiﬁcance was set at a p b 0.05.
Results
179 patients who received clopidogrel and 149 who received
prasugrel were included in this study. The baseline demographic and
clinical characteristics were similar (Table 1). There was signiﬁcantly
more men in the prasugrel group (71.1% vs 59.2%; p = 0.02). Patients
loaded with prasugrel were younger (63.0 vs 67.0 p = 0.007) and hadPrasugrel (n = 147) p value
63.0 (SD: 8.9) 0.007
106 (71.1%) 0.02
30.3 (SD: 7.1) 0.61
126 (86%) 1.0
7 (4.8%) 0.79
14 (9.5%) 0.69
119 (81%) 0.46
95 (64.6%) 0.0004
50 (34%) 1.0
134 (91.2%) 1.0
26 (17.7%) 0.88
19 (12.9%) 0.13
32 (21.8%) 0.05
29 (19.7%) 1.0
8 (5.4%) 0.02
54 (SD: 11) 0.44
0 0.5
1.0 (SD: 0.4) 0.01
0 0.009
4 (2.7%) 0.008
12 (8.2%) 0.001
31 (21.1%) 0.01
106 (71.1%) 0.05
10 (6.7%)
11 (7.5%) 0.69
3 (2.0%) 0.66
33 (22.4%) 0.79
100 (68.0%) 0.56
11 (7.5%) 0.69
84 (57.1%) 0.5
23 (15.6%) 0.39
12 (8.2%) 0.52
3 (2.0%) 1.0
graphy.
Table 2
Procedural characteristics and discharge medications.
Variable Clopidogrel (n = 179) Prasugrel (n = 147) p value
Angiographic success 97.2% 98.4% 0.34
Target coronary vessel
Left main 5 (2.8%) 4 (2.7%) 1.0
Left anterior descending 77 (43%) 74 (50.3%) 0.22
Left circumﬂex 43 (24%) 40 (27.2%) 0.61
Right 67 (37.4%) 48 (32.7%) 0.42
Saphenous vein graft 11 (6.1%) 9 (6.1%) 1.0
Procedural characteristic
Access radial 23 (12.8%) 27 (18.4%) 0.21
Glycoprotein IIb/IIIa inhibitor 3 (1.7%) 2 (1.3%) 1.0
Type A or B1/B2 lesion 63.5% 38.0% 0.0001
Type C lesion 36.5% 62.0%
Stented lesions (n) 281 (1.57/patient) 255 (1.73/patient)
Drug-eluting stent 1.26/patient 1.61/patient
Bare metal stent 0.51/patient 0.12/patient
Complications
Bleeding from entry site 0 0
Access site hematoma 6 3 0.3
Discharge medications
Aspirin 172 (96.1%) 142 (96.6%) 1.0
Β blocker 132 (73.7%) 96 (65.3%) 0.11
Angiotensin converting enzyme inhibitor 86 (48%) 56 (38.1%) 0.07
Angiotensin receptor blocker 26 (14.5%) 24 (16.3%) 0.76
Statin 159 (88.8%) 127 (86.4%) 0.61
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(15.6% vs 2.7%; p = 0.008), and heart failure history (12.8% vs
5.4%; p = 0.05). More patients in the clopidogrel group reported
previous PCI (31.8% vs 21.8%; p = 0.05).
Most patients were discharged with aspirin, a statin, and an angio-
tensin converting enzyme inhibitor/angiotensin receptor blocker, and
a beta blocker, unless contraindicated, with no statistically signiﬁcant
differences between the 2 groups (Table 1). The procedural characteris-
tics are summarized in Table 2. Angiographic success was attained in
nearly all patients (97.2% of those on clopidogrel and 98.4% of those
on prasugrel); the target arteries were similar. Patients treated with
clopidogrel during PCI had relatively more type A or B lesions treated
endless type C lesions (p = 0.0001).
There were minor differences between the in-hospital and 30-day
ischemic and bleeding events between the 2 groups (Tables 3 and 4).
During hospitalization, 2 patients died in the prasugrel group, one of
which experienced a dissection of his right coronary artery following
PCI resulting in an inferior MI while the other patient died of refractory
ventricular tachycardia. No patients from the clopidogrel group died
during hospitalization. Unstable angina during hospitalization occurred
in 1 patient from each group. The patient from the clopidogrel group
was found to have edge dissections from the stent deployments
requiring further stenting.Table 3
In-hospital complications.
Outcome Clopidogrel
(n = 179)
Prasugrel
(n = 147)
p value
Major adverse cardiac events 1 3 0.33
Death 0 2 0.21
Cardiac death 0 1 0.45
Q-wave myocardial infarction 0 1 0.45
Unstable angina pectoris 1 1 0.45
Stent thrombosis 0 0
TIMI major bleeding 0 0
Transfusion 0 1 0.45
TIMI minor bleeding 2 0 0.5
Gastrointestinal bleeding 1 0 1.0
Retroperitoneal bleeding 1 0 1.0In-hospital access site hematomaswere observed in 3 patients in the
prasugrel group, one of which was severe enough to require blood
transfusion and surgical evacuation. Six patients in the clopidogrel
group also experienced access site bleeding, one of which with a large
retroperitoneal bleeding which did not require blood transfusion.
MACE within 30 days of the index procedure were observed in 4
patients in the prasugrel group and in 2 patients in the clopidogrel
group. In the prasugrel group, this corresponded to the 2 patient
deaths detailed above and 2 instances of unstable angina, 1 of
which was managed medically while the other required further
stenting. In the clopidogrel group, this corresponded to unstable angina
experienced by 2 patients requiring revascularization, 1 of which suf-
fered a Q-wave MI following a dissection of the ﬁrst diagonal artery.
Only 1 patient in the prasugrel group experienced TIMI major bleeding
within 30 days requiring blood transfusion as well as cauterization of a
duodenal ulcer due to upper GI bleeding. None of the differences in
outcomes detailed above reached statistical signiﬁcance.
Discussion
The present retrospective study was undertaken to examine
the efﬁcacy and safety of prasugrel (compared to clopidogrel) in a
subset of patients undergoing PCI for non-urgent indications and
anticoagulated with bivalirudin. Several randomized trials compar-
ing the efﬁcacy and safety of prasugrel and clopidogrel in patients
undergoing PCI have been reported. The preponderance of the stud-
ies is in higher risk patients. Most of these studies used heparin as the
primary anticoagulant. The Prasugrel in Comparison to Clopidogrel
for Inhibition of Platelet Activation and Aggregation—Thrombolysis
in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) trial [7] found that
in patients undergoing elective PCI, prasugrel achieved greater
platelet inhibition than did clopidogrel after a loading dose and dur-
ing maintenance treatment. The TRITON-TIMI 38 trial [1] compared
clinical and bleeding events in patients with acute coronary syn-
drome undergoing planned PCI. Only 3% of patients from each
group received bivalirudin. Patients treated with prasugrel had a sig-
niﬁcantly lower rate of ischemic events with a hazard ratio of 0.81
(95% conﬁdence interval 0.73 to 0.90; p b 0.001), favoring prasugrel.
Table 4
Adverse events at 30 days.
Outcome Clopidogrel
(n = 179)
Prasugrel
(n = 147)
p value
Major adverse cardiac events 2 4 0.41
Death 0 2 0.21
Cardiac death 0 1 0.45
Q-wave myocardial infarction 1 1 1.0
Unstable angina pectoris 2 2 1.0
Symptom driven revascularization 1 1 1.0
Stent thrombosis 0 0
TIMI major bleeding 0 1 0.45
TIMI minor bleeding 4 7 0.24
Gastrointestinal bleeding 1 4 0.18
Retroperitoneal bleeding 1 0 1.0
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were lower. However, there was an increased risk of major bleeding
(2.4% with prasugrel vs 1.8% with clopidogrel, hazard ratio1.32, 95%
conﬁdence interval 1.03 to 1.68; p = 0.03). No differences were
found in overall mortality. Of note, 4 (2.7%) of patients in the
prasugrel group of our study had a history of cerebrovascular disease
which is a contraindication for using prasugrel based on TRITON-
TIMI 38 trial.
Several trials have compared the use of bivalirudin to heparin
for intraprocedural antithrombin use. The results of the Acute
Catheterization and Urgent Intervention Triage strategY (ACUITY)
trial [3], which included an acute coronary syndrome population,
favored the use of bivalirudin. The rates of ischemic events were
similar but the bleeding rates were lower. The thienopyridines
used were clopidogrel (64.2% in the group using bivalirudin) and
ticlopidine. The Harmonizing Outcomes with Revascularization and
Stents (HORIZONS) trial [4] randomized patients with ST-segment
elevation MI to heparin or bivalirudin. In nearly all cases, bivalirudin
patients received clopidogrel as the antiplatelet agent. Just as with
other trials, the 30-day rates of major bleeding and net adverse clinical
events were signiﬁcantly reduced in the group receiving bivalirudin.
In the present study, there were no statistically signiﬁcant differ-
ences between both groups in terms of ischemic or bleeding complica-
tions with a slight tendency towards more bleeding in the prasugrel
group. Although it has been previously established that the use of
prasugrel might be more cost-effective than clopidogrel in patients
with acute coronary syndrome undergoing PCI, [8] clopidogrel is now
available as a generic and is available at a lower price whichmay signif-
icantly alter those cost calculations. The strategy of loading patients
needing PCI with prasugrel 60 mg immediately prior to coronary inter-
vention, and then continuation of antiplatelet therapy with 75 mg
clopidogrel daily appeared to be safe and effective in a pilot study [9].
Utilizing this strategy may allow for the “best of both worlds,” withquick efﬁcacy of loading with prasugrel combined with the cost savings
of long-term clopidogrel use. The comparison between different
thienopyridines has not been studied before in patients undergoing
PCI for non-urgent indications.Study limitations
The generalizability of our results is limited because of the
observational, retrospective, single-center nature of our study. Although
the 2 groups had minor differences (Tables 1 and 2), important factors
inﬂuencing the operating physician's choice of antiplatelet agent
might not have been identiﬁed. Only the 30-day follow-up data were
reported. Thus, present analysis provided no information with regard
to the safety or effectiveness of prasugrel after 30 days.Conclusions
In this retrospective analysis, at 30 days, therewere nodifferences in
MACE or bleeding complications between patients anticoagulated with
bivalirudin and given either clopidogrel and prasugrel during PCI for
non-urgent indications.References
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